Life after CAR T for multiple myeloma
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
['FUNDING_R01'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11145971
This project will follow people with relapsed or refractory multiple myeloma who received CAR T to learn about their symptoms, quality of life, and immune changes after treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11145971 on ClinicalTrials.gov |
What this research studies
You'll join a prospective group of real-world patients with relapsed/refractory multiple myeloma who received CAR T at Moffitt Cancer Center. Researchers will collect patient-reported outcomes on symptoms, mood, and social support alongside blood and bone marrow samples over time. They will study inflammation and the bone marrow immune environment together with psychosocial measures to see how immune changes and factors like anxiety relate to recovery and survivorship. The goal is to reflect the experiences of more diverse patients treated outside clinical trials to guide future follow-up care and support after CAR T.
Who could benefit from this research
Good fit: Ideal candidates are adults with relapsed or refractory multiple myeloma who have received CAR T treatment, particularly those treated at or willing to travel to Moffitt Cancer Center for follow-up and sample collection.
Not a fit: Patients who have never received CAR T or who cannot attend clinic visits or provide blood or bone marrow samples are unlikely to benefit directly from participating.
Why it matters
Potential benefit: If successful, this work could help tailor follow-up care and supportive services to improve quality of life and long-term outcomes for CAR T recipients with multiple myeloma.
How similar studies have performed: Clinical CAR T trials have shown strong response rates and improved patient-reported outcomes, but they had strict eligibility and limited diversity, so this real-world cohort is a relatively new approach.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OSWALD, LAURA B. — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: OSWALD, LAURA B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.